Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. (June 2018)

• Record Type: Journal Article
• Authors: Marchioni, Michele; Harmouch, Sabrina S.; Nazzani, Sebastiano; Bandini, Marco; Preisser, Felix; Tian, Zhe; Kapoor, Anil; Cindolo, Luca; Briganti, Alberto; Shariat, Shahrokh F.; Schips, Luigi; Karakiewicz, Pierre I.
• Is Part Of: Cancer epidemiology. Volume 54(2018:Jun.)
• Page Start: 112
• Page End: 118
• Publication Date: 2018-06
• Subjects: Kidney cancer -- Metastatic renal cell carcinoma -- Non-clear cell renal cell carcinoma -- SEER database -- Racial disparities; Cancer -- Epidemiology -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Diagnosis -- Periodicals; Carcinogenesis -- Periodicals; 616.994005
• DOI: 10.1016/j.canep.2018.04.006
• Languages: English
• ISSNs: 1877-7821

Abstract

Highlights: African-American race effect on CSM differs according to mRCC histologic subtype. In ccmRCC African-Americans experienced higher CSM than Caucasians. In non-ccmRCC African-Americans experienced lower CSM respect Caucasians. Differences based on race are independent of access to CNT. These differences may have an impact on efficacy or access to systemic therapies. Abstract: Aim: To test the effect of African-American race on cancer specific mortality (CSM) in clear cell metastatic renal cell carcinoma (ccmRCC) and non-ccmRCC. Patients and methods: Within Surveillance, Epidemiology and End Results registry (2001–2014), we identified patients with ccmRCC and non-ccmRCC. We relied on propensity score (PS) matching to reduce the effect of inherent differences between African-American vs. Caucasian patients. After PS matching that included access to cytoreductive nephrectomy (CNT), cumulative incidence, competing-risks regression (CRR) models and landmark analyses tested the effect of race on CSM. Results: Before PS matching, African-American patients accounted for 7.0 and 24.5% of respectively ccmRCC (N = 6742) and non-ccmRCC patients (N = 766). After PS matching, African-American patients accounted for 22.3 and 33.5% of respectively ccmRCC (N = 2050) and non-ccmRCC (N = 391) matched cohorts. In multivariable CRR models focusing on ccmRCC, higher CSM was recorded in African-Americans (HR:1.27, p < 0.001). Conversely, in non-ccmRCC, lower CSM was recorded in African-Americans (HR:0.54, p < 0.001). Landmark analyses rejected the hypothesis of immortal time bias. Conclusion: African-Americans experienced higher CSM in ccmRCC. Conversely, African-Americans experienced lower CSM, when diagnosed with non-ccmRCC. These differences are independent of access to CNT and warrant further study since they may have an impact on efficacy or access to systemic therapies.